Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial

By van Poznak C.  

Breast Cancer Research and Treatment, Vol. 66, Iss. 3, 2001-04 ,pp. : 239-248

Springer Publishing Company

Access to resources Recommend Favorite

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

By Somlo G.   Martel C.   Lau S.   Frankel P.   Ruel C.   Gu L.   Hurria A.   Chung C.   Luu T.   Morgan R.   Leong L.   Koczywas M.   McNamara M.   Russell C.   Kane S.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 899-906

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

By Jerusalem Guy   Fasolo Angelica   Dieras Veronique   Cardoso Fatima   Bergh Jonas   Vittori Luc   Zhang Yufen   Massacesi Cristian   Sahmoud Tarek   Gianni Luca  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 447-455

Springer Publishing Company

Access to resources Recommend Favorite

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

By Lobo Christopher   Lopes Gilberto   Baez Odalys   Castrellon Aurelio   Ferrell Annapoorna   Higgins Connie   Hurley Erin   Hurley Judith   Reis Isildinha   Richman Stephen   Seo Pearl   Silva Orlando   Slingerland Joyce   Tukia Keleni   Welsh Catherine   Glück Stefan  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 427-435

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

By Hayashi Hidetoshi  

Breast Cancer, Vol. 20, Iss. 2, 2013-04 ,pp. : 131-136

Springer Publishing Company

Access to resources Recommend Favorite